Millendo Gets European Foothold With Alizé Acquisition
The US company is getting hold of livoletide, the French firm's late-stage ready compound for reducing hyperphagia, or insatiable hunger, in patients suffering from the rare genetic disease Prader-Willi Syndrome.
You may also be interested in...
The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.
OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.